LAIs in Schizophrenia:
Can Earlier Adoption Lead to Better Outcomes? Part 2

LAIs in Schizophrenia: Part 2

Course Description/Overview

This Expert Exchange webcast provides learners with a concise educational experience featuring two clinical experts exploring real-world approaches to patient care.

Target Audience

This activity has been designed to meet the educational needs of psychiatrists and other healthcare providers who manage patients with schizophrenia.


Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  1. Describe the impact of LAI antipsychotics on adherence in patients with schizophrenia.
  2. Synthesize the recent data on LAIs on health outcomes for schizophrenia.
  3. Appraise potential pharmacoeconomic advantages of using LAI antipsychotics.
  4. Summarize the role of LAI antipsychotics in early schizophrenia.

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Ralph Aquila, MD Speakers’ Bureau: H. Lundbeck A/S; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc; Sunovion Pharmaceuticals Inc.
Leslie L. Citrome, MD Consultant/Advisor: ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan plc; FORUM Pharmaceuticals Inc.; H. Lundbeck A/S; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc; Pfizer Inc.; Shire; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd; Vanda Pharmaceuticals

Speakers’ Bureau: ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan plc; H. Lundbeck A/S; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc; Pfizer Inc.; Shire; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd; Vanda Pharmaceuticals

Stock Ownership: Bristol-Myers Squibb Company; Eli Lilly and Company; Johnson & Johnson Services, Inc; Pfizer Inc.

Non-faculty

Steven Scrivner, MPA, CHCP; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by independent educational grants from Otsuka America Pharmaceutical, Inc, Lundbeck, and Alkermes, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Novus Medical Education.

CME CREDIT (PHYSICIANS)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Novus Medical Education. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

DISCLOSURE OF UNLABELED USE:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Novus Medical Education, and Otsuka America Pharmaceutical, Inc, Lundbeck, and Alkermes, Inc. do not recommend the use of any agent outside of the labeled indications.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION

In order to claim credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

Release date: March 21, 2018
Expiration date: March 20, 2019